The El Escorial criteria: Strengths and weaknesses

Federica Agosta, Ammar Al-Chalabi, Massimo Filippi, Orla Hardiman, Ryuji Kaji, Vincent Meininger, Imaharu Nakano, Pamela Shaw, Jeremy Shefner, Leonard H. Van Den Berg, Albert Ludolph

Research output: Contribution to journalArticlepeer-review


The El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis (ALS) were established 20 years ago and have been used as inclusion criteria for clinical trials. However, concerns have been raised concerning their use as diagnostic criteria in clinical practice. Moreover, as modern genetics have shed new light on the heterogeneity of ALS and the close relationship between ALS and frontotemporal dementia (FTD) recognized, the World Federation of Neurology Research Group on ALS/MND has initiated discussions to amend and update the criteria, while preserving the essential components for clinical trial enrolment purposes.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Issue number1-2
Publication statusPublished - Mar 1 2015


  • ALS
  • El Escorial

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)


Dive into the research topics of 'The El Escorial criteria: Strengths and weaknesses'. Together they form a unique fingerprint.

Cite this